Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole

被引:128
作者
Macedo, Luciana F. [1 ]
Guo, Zhiyong [1 ]
Tilghman, Syreeta L. [1 ]
Sabnis, Gauri J. [1 ]
Qiu, Yun [1 ]
Brodie, Angela [1 ]
机构
[1] Univ Maryland, Sch Med, Hlth Sci Facilities 1, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA
关键词
D O I
10.1158/0008-5472.CAN-05-3984
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous work has shown that androgens inhibit breast cancer cells and tumor growth. On the other hand, androgens can be converted to mitogenic estrogens by aromatase in breast cancer cells. Here, we report that androgens, such as the aromatizable androstenedione and the non-aromatizable 5 alpha-dihydrotestosterone, inhibit MCF-7 cell proliferation. This effect is observed only in the absence or at a low concentration of estrogens and is evident in cells with low aromatase activity. Growth of a new aromatase stably transfected MCF-7 cell line (Act) was stimulated by conversion of androstenedione into estrogens and was sensitive to aromatase inhibitors. We show that blockade of the androgen receptor (AIR) in these cells by the antiandrogen casodex or by the anti-AR small interfering RNA inhibited the antiproliferative effect of dihydrotestosterone and letrozole (aromatase inhibitor). We also show that suppression of the estrogen-induced antiapoptotic protein Bcl-2 may be involved in the antiproliferative effects of androgens and letrozole. These effects can be reversed by casodex. In conclusion, the results suggest that aromatase inhibitors may exert their antiproliferative effect not only by reducing the intracellular production of estrogens but also by unmasking the inhibitory effect of androgens acting via the AR.
引用
收藏
页码:7775 / 7782
页数:8
相关论文
共 49 条
[11]   Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis [J].
Filardo, EJ ;
Quinn, JA ;
Frackelton, AR ;
Bland, KI .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (01) :70-84
[12]  
GOLDENBERG IS, 1964, JAMA-J AM MED ASSOC, V188, P1069
[13]   CALUSTERONE (7-BETA, 17-ALPHA-DIMETHYLTESTOSTERONE) AS PRIMARY AND SECONDARY THERAPY OF ADVANCED BREAST-CANCER [J].
GORDAN, GS ;
HALDEN, A ;
HORN, Y ;
FUERY, JJ ;
PARSONS, RJ ;
WALTER, RM .
ONCOLOGY, 1973, 28 (02) :138-146
[14]   Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17 [J].
Goss, PE ;
Ingle, JN ;
Martino, S ;
Robert, NJ ;
Muss, HB ;
Piccart, MJ ;
Castiglione, M ;
Tu, DS ;
Shepherd, LE ;
Pritchard, KI ;
Livingston, RB ;
Davidson, NE ;
Norton, L ;
Perez, EA ;
Abrams, JS ;
Cameron, DA ;
Palmer, MJ ;
Pater, JL .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1262-1271
[15]   Inhibition of MCF-7 breast cancer cell proliferation by 5α-dihydrotestosterone;: a role for p21Cip/Waf1 [J].
Greeve, MA ;
Allan, FK ;
Harvey, JM ;
Bentel, JM .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2004, 32 (03) :793-810
[16]   Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells [J].
Huang, HJ ;
Zegarro-Moro, OL ;
Benson, D ;
Tindall, DJ .
ONCOGENE, 2004, 23 (12) :2161-2176
[17]  
INGLE JN, 1991, CANCER-AM CANCER SOC, V67, P886, DOI 10.1002/1097-0142(19910215)67:4<886::AID-CNCR2820670405>3.0.CO
[18]  
2-O
[19]   Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model [J].
Jelovac, D ;
Macedo, L ;
Goloubeva, OG ;
Handratta, V ;
Brodie, AMH .
CANCER RESEARCH, 2005, 65 (12) :5439-5444
[20]   Effects of exemestane and tamoxifen in a postmenopausal breast cancer model [J].
Jelovac, D ;
Macedo, L ;
Handratta, V ;
Long, BJ ;
Goloubeva, OG ;
Ingle, JN ;
Brodie, AMH .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7375-7381